Abstract
BackgroundThis study aimed to evaluate patterns of posttransplant malignancies among renal transplant recipients (RTRs) in South Korea using nationwide data.MethodsThe nationwide cohort assessed in this study included RTRs from January 1, 2010, to December 31, 2014. We analyzed cancer incidence during the time course after renal transplantation. Additionally, we calculated standardized incidence ratios (SIRs) to evaluate the risk of malignancies in RTRs.ResultsA total of 1343 RTRs (871 males and 472 females, mean age 48.5 ± 11.6 years) were assessed. Among them, 104 (7.7%) developed malignancies after transplantation, most commonly in the thyroid cancer (23.1%). The SIR for all cancers was 3.54; particularly, the SIRs for renal cancer, myeloma, and non-Hodgkin lymphoma were 16.31, 24.02, and 28.64, respectively. Females showed a higher risk of malignancy than males (SIRs: 4.04 for women and 3.26 for men). The median interval between transplantation and malignancy diagnosis was 27.2 months (range 12.3–54.8 months).ConclusionsRTRs in South Korea demonstrated a high risk of malignancy after transplantation compared with the general population. This indicates that close surveillance and routine screening for cancer in RTRs are needed.
Highlights
This study aimed to evaluate patterns of posttransplant malignancies among renal transplant recipients (RTRs) in South Korea using nationwide data
We aimed to analyze cancer risk among RTRs based on a large population cohort, using claims data from the Health Insurance Review and Assessment Service (HIRA) in South Korea
Overall cancer risk was significantly increased in RTRs compared with the general population (SIR 3.54, 95% Confidence interval (CI) 2.89–4.29; Table 3)
Summary
This study aimed to evaluate patterns of posttransplant malignancies among renal transplant recipients (RTRs) in South Korea using nationwide data. Renal transplant recipients (RTRs) have been shown to have a higher cancer risk than the general population [3], and posttransplant malignancy is one of the major prognostic factors of mortality among RTRs [4, 5]. This is partly attributed to immunosuppression-associated malignancies in patients receiving RT [6, 7]. We aimed to analyze cancer risk among RTRs based on a large population cohort, using claims data from the Health Insurance Review and Assessment Service (HIRA) in South Korea
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
